Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR1701 +/- SHR2554 in R/R cHL
NCT05896046Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa in classical Hodgkin lymphoma (cHL), sponsored by Chinese PLA General Hospital. Started Jun 2023; status: recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT05896046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05896046.